FD&C ACT VIOLATIONS OF COUNTERFEITING AND MISBRANDING AMPICILLIN
FD&C ACT VIOLATIONS OF COUNTERFEITING AND MISBRANDING AMPICILLIN capsules were admitted by former Premo exec John Blackman in New Jersey Federal Court March 5. Blackman pleaded guilty to three criminal misdemeanor counts in connection with the mislabeling and illegal distribution of 1.3 mil. ampicillin capsules in late 1980 and early 1981. According to the indictment, Premo Pharmaceuticals purchased the bulk ampicillin from Pierrel America, based on the U.S. Virgin Islands (St. Croix), in December of 1980. The drugs were labeled with April and June 1981 expiration dates, which Blackman changed to 1984 expiration dates, in addition to falsifying the lot numbers of the drugs. The former Premo VP pleaded guilty to falsifying the expiration dates and lot numbers, and to labeling the ampicillin capsules as Biocraft products. The indictment states that: "Without authorization from Biocraft, he [Blackman] packaged the capsules with copies Biocraft package inserts and labeled them with copies of Biocraft labels, thereby representing them to be the product of . . . Biocraft." Blackman also pleaded guilty to a charge of introducing the misbranded drug into interstate commerce. The ampicillin was delivered to New York pharmacist Jay Greenblatt, who was also indicted. Greenblatt, who was employed by Casson Pharmacy in Queens Village, NY, pleaded guilty to two criminal misdemeanor charges of introducing the misbranded drugs into the interestate commerce. The pharmacy's owner was not indicted. Originally indicted on criminal felony charges, the two men pleaded guilty to reduced criminal misdemeanor counts carrying a maximum sentence of one year in prison and $1,000 fine per count. Blackman could receive a maximum three year prison sentence and $3,000 fine, Greenblatt a maximum two years in prison and $2,000 fine. Sentencing is set for April 13. Blackman, son of Premo President Seymour Blackman, was fired from his position as Premo VP in early 1981 following Premo's discovery of printer's invoices for the counterfeit Biocraft labels and package inserts, and the disappearance of the ampicillin from Premo's New Jersey warehouse.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth